• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infectious Diseases and Therapy >In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections
【24h】

In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections

机译：口服头孢菌素（Cefprozil和头孢克肟）对社区获得性泌尿道感染耐环丙沙星肠杆菌科细菌的体外活性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction The global emergence of pathogens of urinary-tract infections resistant to ciprofloxacin or producing extended-spectrum β-lactamases (ESBL) led us to investigate the activity of older antimicrobials such as cefprozil and cefixime against a recent broad collection of urine enterobacteria from 2012 and 2013. Methods Minimum inhibitory concentrations and minimum bactericidal concentrations of cefprozil, cefixime and ciprofloxacin were determined against 293 Escherichia coli (40 ESBL producers), 54 Klebsiella pneumoniae (10 ESBL producers) and 53 Proteus mirabilis isolates. Results Cefprozil was more active than ciprofloxacin against non-ESBL-producing E. coli (93.7% vs 80.2%, p Conclusion Results suggest that cefprozil and cefixime remain a good therapeutic alternative against urine enterobacteria particularly in case of ciprofloxacin-resistant pathogens. Their activity against ESBL-producing pathogens is limited.
机译：引言对环丙沙星耐药或产生广谱β-内酰胺酶（ESBL）的泌尿道感染病原体的全球出现使我们研究了较旧的抗菌药物（如头孢曲唑和头孢克肟）对最近从2012年开始收集的尿液肠杆菌的活性。 2013年。方法确定了对293大肠杆菌（40个ESBL生产者），54例肺炎克雷伯菌（10个ESBL生产者）和53株奇异变形杆菌的最小抑菌浓度和最小杀菌浓度。结果头孢曲唑比环丙沙星对产生非ESBL的大肠杆菌更具活性（93.7％对80.2％，p）结论结果表明，头孢曲唑和头孢克肟仍然是抵抗尿肠杆菌的良好治疗选择，特别是在对环丙沙星耐药的病原体的情况下。针对产生ESBL的病原体是有限的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号